Organization
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China
2 abstracts
Abstract
Claudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial.Org: Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Beijing Cancer Hospital, Beijing, China, Department of Gastrointestinal Oncology, Beijing Cancer Hospital, Beijing, China, Peking University Cancer Hospital and Institute, Beijing, China,
Abstract
Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies.Org: Peking University Cancer Hospital and Institute, Beijing, China, The First Affiliated Hospital of Henan University of Science and Technology, Shanghai East Hospital, Zhongnan Hospital of Wuhan University, The First Affiliated Hospital of Xinxiang Medical University,